ArticleJournal of health economics and outcomes research2023

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review.

Goran Bencina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.